| 2016 | Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients | 문영철 | Article |
| 2015 | Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial | 문영철 | Meeting Abstract |
| 2018 | Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) | 이경은 | Article |
| 2008 | Final Report of "Korean Multicenter AML-2000 Trial": Intention to Treat Analysis Based on Cytogenctics Risk | 문영철 | Meeting Abstract |
| 2016 | Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study | 문영철 | Article |
| 2009 | Induction Therapy with "3+7" Chemotherapy Plus ATRA Followed by Consolidations with Three Courses of Idarubicin Alone and Maintenance Therapy with ATRA in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Has An Excellent Leukemia-Free Survival but Minimal Toxicity in Low and Intermediate Risk Groups | 성주명; 문영철 | Meeting Abstract |
| 2020 | Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) | 문영철 | Article |
| 2022 | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia | 성주명; 문영철; 김대영; 박영훈 | Article |
| 2015 | Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib | 문영철 | Meeting Abstract |
| 2009 | Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer | 이순남 | Article |
| 2012 | Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party | 성주명 | Meeting Abstract |
| 2012 | TREATMENT OUTCOMES OF GEMCITABINE VERSUS GEMCITABINE PLUS PLATINUM FOR BILIARY TRACT CANCER: A KOREAN CANCER STUDY GROUP RETROSPECTIVE ANALYSIS | 남은미 | Meeting Abstract |
